Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue

While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.

While public investors have proven relatively receptive to biopharma IPOs lately, the anticipation of those deals’ issuers remains a step ahead of the market: the final share price of deals closed so far this year averages 16% below the midpoint of the anticipated price range for those IPOs priced above $5 per share (excluding, that is, the deals of Canadian DiaMedica Inc. , London’s Neuropharm Group PLC , and Israeli BioLineRx Ltd. ) [See Deal][See Deal][See Deal] While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions. (See "Bad Haircuts: 2005's Biotech IPOs--Getting Out at Any Price?" START-UP, March 2005. Also see "Bad Haircuts: 2005's Biotech IPOs--Getting Out at Any Price?" - Scrip, 1 March, 2005.)

This year those exceptions were Chinese bioinjectables manufacturer 3SBio Inc., which netted $107 million in February [See Deal], and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Executives On The Move: New CEOs At Sun Pharma And TME Pharma

Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.